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Abstract The activated c-myc allele in Burkitt’s lymphoma is
associated with a clustering of somatic mutations within a
discrete domain of intron I that define protein recognition
sequences, designated as myc intron factors (MIF-1, MIF-2 and
MIF-3). We have previously shown that MIF-1 binding activity
consists of two polypeptides, myc intron binding polypeptide
(MIBP1) and RFX1. In the present study we identified two
polypeptides, p105 and p115, and showed that these proteins give
rise to a DNA^protein complex at the MIF-2 as well as the
adjacent MIF-1 site. In addition, we demonstrated that all four
proteins interact with a novel MIF-1 like motif upstream from
the c-myc promoter region, designated 5PMIF. These data
suggest a model, where the interactions of MIBP1/RFX1 and
p105/p115 with the MIF-like sites may play a role in the
promoter topology of the c-myc gene.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The expression of the protooncogene c-myc is linked with
cell proliferation, di¡erentiation and the development of hu-
man tumors. The regulation of c-myc gene expression is con-
trolled by several protein factors and their cis elements that
have been identi¢ed in the 5P upstream and untranslated exon
I regions of the c-myc gene [1^3]. In addition, several discrete
protein binding sites have been identi¢ed within intron I near
the boundary of exon I designated myc intron factors (MIF-1,
MIF-2 and MIF-3) [4,5]. MIF-1 was shown to bind a nuclear
phosphoprotein and it was demonstrated that protein binding
was abolished by a point mutation present in the correspond-
ing region of a Burkitt’s lymphoma c-myc DNA [4,6]. Char-
acterization of the MIF-1 binding site indicated that MIF-1
activity consisted of two polypeptides, the myc intron binding
polypeptide (MIBP1) and the major histocompatibility
(MHC) class II promoter-binding protein RFX1 [7]. RFX1
was initially identi¢ed as a protein that binds to the X-box
sequence in the promoter of the MHC class II gene and sub-
sequently shown to function as a transactivator of the hepa-
titis B virus (HBV) enhancer through its interaction with the
EP binding element [8^10]. In addition, RFX1 was shown to
regulate several other mammalian genes, including the human
leukemia (PCNA) promoter and the interleukin 5 receptor
K promoter [11,12]. The RFX-type transcription factor Daf-19
was recently shown to regulate sensory neuron cilium forma-
tion in Caenorhabditis elegans [13]. It has been previously
shown that RFX1 associates in vivo with MIBP1 and that
this heterodimer is present, by gel shift analysis, in the slower
migrating ‘A’ complex at the c-myc (MIF-1) site, at the MHC
class II (X-box) RFX binding site, [7,9] and at the regulatory
regions of several viral genes, including HBV, Epstein Barr
virus, cytomegalovirus and polyoma virus [7,10,14,15]. It was
also shown recently that protein levels and DNA binding
activity of RFX1 and MIBP1 are induced during granulocytic
di¡erentiation of HL60 cells, which correlated with a decrease
in c-myc levels in these cells in vivo [16].
There are two additional DNA^protein complexes that
have been observed by gel shift analysis to form at the
c-myc (MIF-1) site designated components ‘B’ and ‘C’ [7,15].
DNA^protein complexes ‘A’ and ‘B’ are present at the c-myc
(MIF-1), MHC class II (RFX), HBV (EP) and other viral
sites, while ‘complex C’ is unique to the MIF-1 and the ad-
jacent MIF-2 binding sequences and has not been detected at
the RFX and the EP recognition sites [7,15]. In this study we
identi¢ed two polypeptides, p105 and p115 that give rise to
‘complex C’ at the MIF-1 and MIF-2 recognition sites. In
addition, we showed that all four proteins, MIBP1/RFX1
and p105/p115, interact with a novel MIF like motif 600
base pair upstream from the c-myc promoter region, desig-
nated as 5PMIF. We also showed that MIF-1 [7,15] and
MIF-2 but not the 5PMIF recognition sequence can regulate
heterologous promoter activity in vivo. These data suggest a
model, where the interaction of MIBP1/RFX1 and p105/p115
with three MIF-like sites may play a role in the promoter
topology of the c-myc gene.
2. Materials and methods
2.1. Plasmids and oligonucleotide probes
Double-stranded oligonucleotides were synthesized as follows:
MIF-1, GATCTAGAGTAGTTATGGTAACTGGG; MIF-2, GAT-
CACCTTATGAATATATTCACACA; 5PMIF, GATCCGCGTTGC-
TGGGTTATTTTAATCA. The double stranded oligonucleotides
were multimerized and fragments containing ¢ve tandem copies
were gel-puri¢ed and cloned into the BglII site of the pCAT-P vector
(Promega) as described previously [7]. All plasmids were con¢rmed by
sequencing. The pGL2-P luciferase vector (Promega) was used to
correct for transfection e⁄ciency.
2.2. Cell culture and DNA transfections
HeLa cells were obtained from the American Type Culture Collec-
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tion (ATCC). The cells were grown in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) (Bio£uids) with 10% fetal calf serum and 50 mg
each of streptomycin and penicillin per ml. For each transfection,
2.0U106 cells were plated in 100 mm dishes and incubated overnight
at 37‡C. Cells were transfected by calcium phosphate precipitation for
5 h using either 5 mg of pCAT-P or pCAT-P containing an insert
consisting of one to ¢ve copies of the indicated DNA binding site. 1 Wg
of pGL2-Luc was cotransfected to control for transfection e⁄ciency.
At 42 h the dishes were washed with cold phosphate bu¡ered saline
(PBS), scraped and the cell pellets were resuspended in 100 Wl of 100
mM KH2PO4 pH 7.8 with 1 mM DTT and stored at 320‡C. CAT
and luciferase assays were performed as described previously [5,17].
2.3. Preparation of nuclear and whole-cell extracts
Nuclear extracts were prepared according to the modi¢ed method
of Schreiber [18]. Pelleted cells were resuspended in bu¡er A (10 mM
hydroxyethyl-piperazine N-2P-ethanesulfonic acid (HEPES) pH 7.5, 10
mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM dithiothreitol
(DTT) and 0.5 mM phenylmethylsulfonyl £uoride (PMSF)) and Non-
idet p-40 (NP-40) was added to a ¢nal concentration of 0.5%. Nuclei
were pelleted and resuspended in bu¡er C (20 mM HEPES pH 7.5, 0.4
M KCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5 mM Na ortho-
vanadate 1 mM DTT and 1 mM PMSF). Both bu¡ers contained 0.02
Wg/Wl of freshly prepared aprotinin and leupeptin. Supernatants were
cleared by centrifugation after 15 min at 4‡C and were frozen in
aliquots at 370‡C. The whole-cell extract was prepared by resuspend-
ing 1 g of cell pellet in 3 ml of bu¡er A (10 mM HEPES, pH 7.9, 10
mM MgCl2, 1 mM DTT) and incubated for 30 min at 4‡C. The cell
suspension was then adjusted to 0.35 M KCl, the mixture was agitated
gently for 20 min at 4‡C and microfuged for 15 min at 4‡C. The
supernatant was collected, glycerol added to 20%, and stored at
370‡C.
2.4. Production of antiserum speci¢c for MIBP1 and RFX1
Rabbit antiserum was raised against an oligo-a⁄nity puri¢ed
MIBP1 protein from HeLa cells as described [7]. Rabbit antiserum
to RFX was raised against N-terminal peptide as described previously
[7,9].
2.5. Electrophoretic mobility shift assay
Mobility shift assays were performed as described previously [4,5].
0.1 ng 32P end labeled duplex oligonucleotide probe (approximately
104 cpm/lane) was incubated with 2 Wl of nuclear extract (1 mg/ml
protein) in 10 Wl containing 10 mM HEPES pH 7.8, 75 mM KCl, 2.5
mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 3% Ficoll, and 1 Wg poly-
(dI-dC). Where indicated, 2 Wl of whole-cell extract (25 mg/ml protein)
in 20 Wl of the reaction mixture containing 10 mM Tris^HCl, pH 7.5,
100 mM KCl, 10 mM MgCl2, 1 mM DTT, 1 mg poly(dI-dC) was
used. In ‘supershift’ antibody experiments, the reaction mixture con-
taining the nuclear extract was preincubated for 5 min at room tem-
perature with 1 Wl of either preimmune serum or serum raised against
MIF-1 protein, before the addition of labeled oligonucleotide probe.
The reaction mixture was incubated for 15 min at room temperature
and analyzed by 4% PAGE as previously described.
2.6. Two-dimensional mobility shift/SDSPPAGE
The mobility shift assay was performed with whole-cell extract as
described above (¢rst dimension). The wet gel was subjected to auto-
radiography and the lanes containing the reaction mixture were ex-
cised and irradiated by UV light in the UV Stratalinker 1800 oven
(Stratagene) using the auto-cross-link program for 10 min. The ex-
cised acrylamide slices were then placed on top of a 7.5% SDS^poly-
acrylamide gel, resolved by electrophoresis and subjected to autora-
diography.
3. Results
3.1. Identi¢cation of a MIF-1-like sequence in the 5P regulatory
region of the c-myc gene
We identi¢ed a MIF-like sequence in the 5P regulatory re-
gion of the human c-myc gene, designated 5PMIF (Fig. 1A).
This 5PMIF sequence includes the GTTGCT motif that has
been identi¢ed as an important contact point in the regulatory
Fig. 1. MIF-1-like sequence within the 5P regulatory region of the
c-myc gene. A: Schematic representation of the MIF-1, MIF-2 and
5PMIF elements in the c-myc gene. The similarities between sequen-
ces are overlined and the binding motif [7] for MIBP1/RFX1 is
shown in dashed line. B: Cross-competition analysis of the 5PMIF
binding activity with the MIF-1 oligonucleotide probe. C: Cross-
competition analysis of the MIF-1 binding activity with the 5PMIF
oligonucleotide probe. CCAAT represents a non-speci¢c control oli-
gonucleotide. Probe alone is shown in lanes 1 of both B and C.
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elements found in the enhancer and promoter region of HBV,
Epstein Barr and polyomavirus [8,19^22] that bind similar
protein factors as the c-myc (MIF-1) site [4,7]. To test whether
the 5PMIF site binds similar protein factors, we constructed
synthetic oligonucleotides representing the 5PMIF sequence
and compared MIF-1 and 5PMIF as probes and competitors
in the mobility shift assay (Fig. 1B,C). We observed two
DNA^protein complexes formed with the 5PMIF probe,
which comigrated with the ‘A’ and ‘C’ complexes at the
MIF-1 site (Fig. 1B,C). Complex ‘A’ was more abundant at
the MIF-1 site, while complex ‘C’ was more abundant at the
5PMIF site. DNA^protein complex formation could be
blocked with each probe (Fig. 1B,C lanes 1^8) but not with
unrelated sequences (Fig. 1B,C lanes 9^11).
To examine whether the MIBP1/RFX1 proteins which give
rise to complex ‘A’ at the MIF-1 site [7] also interact specif-
ically with the 5PMIF sequence, we tested the e¡ect of anti-
MIBP1 and anti-RFX1 sera on the migration pattern of the
5PMIF^protein complexes. We observed that both anti-
MIBP1 and anti-RFX1 serum speci¢cally retarded the migra-
tion of the ‘A’ complex at both the MIF-1 and 5PMIF probes
(Fig. 2 lanes 4, 6, 10 and 12), while the control preimmune
serum had no e¡ect (Fig. 2 lanes 3, 5, 9 and 11). The ‘super-
shift’ of the ‘A’ complex was identical between the two probes
used (Fig. 2), suggesting that MIBP1 and RFX1 bind to the
c-myc 5PMIF site as well. The MIBP1 and the RFX1 antisera,
however, did not supershift the ‘C’ complex (Fig. 2).
3.2. Similarity between DNA^protein complex formed at
MIF-1 and 5PMIF to the MIF-2 complexes
We previously identi¢ed a 20 bp sequence located adjacent
to the MIF-1 site in intron I of the c-myc gene, designated
MIF-2 [5]. Since we also observed that a MIF-1 oligonucleo-
tide competes for MIF-2 binding [4,5], and since the migration
pattern of the DNA^protein complexes at the MIF-2 site
resembled the migration of the ‘C’ complex formed at the
MIF-1 and 5PMIF sites, we compared the migration pattern
between the MIF-1, MIF-2 and 5PMIF complexes (Fig. 3A).
We observed that complex ‘C’ which formed with both the
MIF-1 and 5PMIF oligonucleotides also comigrated with the
DNA^protein complex formed with the MIF-2 sequence (Fig.
3A). To demonstrate the relative abundance of these com-
plexes, we used an equal amount of cell extracts (2 Wg) for
each probe, which resulted in a weaker signal at the MIF-1
site. Cross-competition analysis demonstrated that unlabeled
MIF-2 oligonucleotides competed with complex ‘C’ at the
5PMIF sequence (Fig. 3B lanes 1^3), and conversely 5PMIF
oligonucleotide competed protein binding at the MIF-2 site
(Fig. 3B lanes 4^6). In addition, comparison of the nucleotide
sequences revealed a C/GTTATG/T motif in the MIF-1,
MIF-2 and 5PMIF sites. These results suggest that the MIF-
2 binding polypeptide(s) may also interact with the adjacent
MIF-1 site as well as with the upstream 5PMIF protein bind-
ing sequence.
3.3. Identi¢cation of polypeptides associated with MIF-2 and
the 5PMIF binding activity
To identify polypeptides associated with MIF-2 and 5PMIF
binding activity, HeLa whole-cell extracts were incubated ei-
ther with 5PMIF or MIF-2 oligonucleotide probes and the
resulting DNA^protein complexes were separated by native
electrophoresis. The lanes containing the retarded protein
complexes were excised, UV irradiated to cross-link the pro-
teins to the oligonucleotide probe, and the gel slice was em-
bedded onto a SDS^polyacrylamide gel, subjected to electro-
phoresis and autoradiography. Using this method we
Fig. 2. anti-MIBP1 and anti-RFX1 sera recognize proteins in the
5PMIF complex. HeLa nuclear extracts were preincubated in the ab-
sence (3) or in the presence of either preimmune serum (P) or
MIF-1 speci¢c immune serum (I).
Fig. 3. MIF-1 and 5PMIF elements in the c-myc gene bind MIBP1/
RFX1 and the MIF-2 binding proteins. A: Analysis of DNA^pro-
tein complexes from HeLa whole-cell extracts formed with MIF-1,
MIF-2 and 5PMIF recognition sites. B: Cross-competition analysis
of DNA^protein complexes formed at MIF-2 and 5PMIF sites.
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identi¢ed two proteins, p105 and p115, which were detected in
the ‘C’ complex at the 5PMIF site (Fig. 4A) as well as at the
MIF-2 site (Fig. 4B). We found that p115 predominates over
the p105 in the 5PMIF complex (at a ratio of 5:1) while the
reverse is observed for the MIF-2 complex (at a ratio of 1:2).
Our results suggest that MIF-1 and 5PMIF oligonucleotide
probes are bound by MIBP1/RFX1 as well as the p105/p115
proteins. The MIBP1/RFX1 complex, however, preferentially
recognized the MIF-1 site while the 115/105 proteins showed
greater a⁄nity for 5PMIF and MIF-2 sequences (Fig. 3A).
3.4. Repressor activity of the MIF-2 element in HeLa cells
To test, whether the MIF-2 and 5PMIF recognition sites
mediate transcriptional regulation we prepared synthetic mul-
timers of either MIF-2 or 5PMIF and cloned these multimers
in the BglII site of the pCAT-P vector [7,15]. The parental
control plasmid and constructs containing the MIF-2 and
5PMIF element clones in either sense or antisense orientation
(in relation to the transcriptional unit of the SV40 promoter)
were transfected into HeLa cells and CAT activity was mea-
sured 42 h after transfection. We observed that the constructs
Fig. 4. Two-dimensional mobility shift SDS^PAGE. A: Mobility
shift assay was performed using 5PMIF oligonucleotide probe (¢rst
dimension). B: Mobility shift using MIF-2 probe. The lane repre-
senting the DNA^protein complexes was cut from the mobility shift
gel and was overlaid onto a 7.5% SDS^PAGE. DNA^protein com-
plex ‘C’ and non-speci¢c (ns) complexes are marked by arrowhead.
The arrows depict two proteins, p105 and p115. Molecular weight
markers are indicated.
Fig. 5. Analysis of promoter activity by MIF-2 and 5PMIF sequen-
ces. Single copy or multimerized sites were cloned into an SV40
CAT expression vector in the BglII site in the proximity of the
SV40 promoter [7,15]. A: CAT activity after transfection of MIF-2
sites. B: CAT activity after transfection of 5PMIF sites. Bar graphs
show analysis of three independent experiments each performed in
duplicate in HeLa cells and adjusted for transfection e⁄ciency by
cotransfection with the pGL2-luciferase vector. (s) and (as): sense
and antisense orientation.
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containing sense and antisense MIF-2 multimerized elements
displayed about four-fold reduction in CAT activity (calcu-
lated as the mean value of six experiments) as compared to
the parent vector (Fig. 5A). Two or three copies of MIF-2
sequence cloned either in antisense or sense orientation, re-
spectively, were su⁄cient to downregulate SV40 promoter ac-
tivity while a single copy of the MIF-2 sequence had no e¡ect
(Fig. 5A). In contrast, the 5PMIF element was not active in
HeLa cells even in multimerized form (Fig. 5B). These and
previous data [7] suggest that the MIF-1 and MIF-2 sequences
play a direct role in the regulation of transcription while the
5PMIF sequence may help to bring protein factors within the
transcriptional initiation site.
4. Discussion
MIF-1 was initially identi¢ed as a binding activity that
associated with a 20 bp sequence in the intron I of the
c-myc gene and was shown to consist of two polypeptides,
the MIBP1 and the MHC class II promoter binding protein
RFX1 [4,6,7,14]. MIF-1-like binding sequences were also
found in the regulatory regions required for promoter and
enhancer activities of MHC class II genes and of several dis-
tinct DNA viral genes, including the HBV, CMV, EBV and
Py genes [7,10,23]. Based on the previously established con-
sensus sequences [7] we detected a MIF-1-like site, termed
5PMIF, within the 5P untranscribed regulatory region of the
c-myc gene. Moreover, we showed that this 5PMIF site also
binds the MIBP1/RFX1 protein complex. Thus, the two c-myc
promoters, P1 and P2, are £anked by MIF cis elements that
interact with the same protein factors.
The MIBP1/RFX1 proteins comprise the retarded complex
‘A’ at both the MIF-1 and the 5PMIF sites. Since the other
two DNA^protein complexes ‘B’ and ‘C’ also showed a sim-
ilar migration pattern between the MIF-1 and 5PMIF, we
tested whether they bound the same protein factors. We
were interested in complex ‘C’ because of its relative abun-
dance at the 5PMIF site and also because complex ‘C’ comi-
grated with both the MIF-1 probe and with the adjacent
MIF-2 protein recognition sequences [7]. We identi¢ed two
proteins in the ‘C’ complex, termed p105 and p115, and dem-
onstrated that these two proteins can bind to all three MIF-1-
like recognition sequences. Low abundance of the ‘B’ complex
did not allow us to identify its protein composition, however,
it was suggested previously that the ‘B’ complex may consists
of other related members of the RFX gene family [24]. Our
results demonstrate that MIBP1/RFX1 gives rise to the ‘A’
complex at both the MIF-1 and 5PMIF elements while p105/
p115 gives rise to the ‘C’ complex formed at all three binding
sites, MIF-1, 5PMIF and MIF-2.
Although the MIBP1/RFX1 and p105/p115 complexes can
both bind the MIF-1 and 5PMIF sequences, the ratio between
the ‘A’ to ‘C’ complexes varied signi¢cantly between MIF-1
and 5PMIF sites. The MIBP1/RFX1 complex binds with high-
er a⁄nity to the MIF-1, while the p105/p115 complex was
more abundant at the 5PMIF site. This preferential recogni-
tion of the MIBP1/RFX1 vs. p105/p115 complexes may be
due to the location of the C/GTTATG/T motif in the MIF-
1, MIF-2 and 5PMIF recognition sequences (overlined in Fig.
1A). For example, the GTTATG sequence overlaps with the
palindromic MIBP1/RXF1 binding site in the MIF-1 recog-
nition sequence, thus a high a⁄nity binding of the MIBP1/
RFX1 may create steric hindrance for p105/p115 binding. In
contrast, the GTTATT motif in the 5PMIF site is situated
between the two palindromic sites, thus making it more acces-
sible for p105/p115 binding. Interestingly, only MIBP1/RFX1
complex can form at the EP element of the HBV enhancer
region and in the X-box sequence in the promoter of the
MHC class II gene [7] since the TTATG/T motif is not present
in these regulatory sites. Such di¡erential recognition of
MIF’s, EP and X-box sequences by either MIBP1/RFX1
or p105/p115 complexes may lead to di¡erential regulation
of the promoter activity in the c-myc, HBV or MHC class
II genes.
Simultaneous binding of MIBP1/RFX1 and p105/115 pro-
teins to all three sites that £ank the promoter region of the
c-myc gene, may play both structural and functional roles by
bringing regulatory molecules into the vicinity of the tran-
scription start site. It has been proposed that the RFX1 ho-
modimer, which has two independent DNA-binding domains,
could interact simultaneously with two di¡erent binding (X-
box) sequences located far apart on the MHC class II DR
gene [9]. Such interactions would cross-link the sites, thus
bringing regulatory sequences into the vicinity of the tran-
scription initiation site. A similar model has been described
for the PRDII-BF1 protein containing two widely separated
zinc ¢nger motifs that could bind simultaneously to two cop-
ies of the same recognition sequence in the L-interferon gene
[25]. Similarly, we have now identi¢ed several MIF sites £ank-
ing the promoter of the c-myc gene. The 5PMIF sequence is
located 600 bp upstream from the initiation start site (P2
promoter) while MIF-1 and MIF-2 sequences are located
400 and 500 bp, respectively, downstream from the initiation
start site. Thus, the observation that these widely dispersed
elements may bind similar protein factors suggests a model in
which MIBP1/RFX1 and p105/p115 may play a role to link
the 5PMIF site to MIF-1 and MIF-2 sites leading to formation
of a loop, and thus bringing regulatory sequences situated far
upstream and downstream within the vicinity of the transcrip-
tion initiation start site. Additional support for this model
comes from the observation that both MIF-1 and MIF-2
but not the 5PMIF sequences contain intrinsic transcriptional
activity, again suggesting that 5PMIF sequence may play a
structural role in promoter topology.
We have previously shown that multimerized MIF-1 se-
quences act as silencers regulating the SV40 promoter in an
orientation and position independent manner while one copy
of MIF-1 sequence had no e¡ect [7]. Similarly, to exhibit
transcriptional repression tandem MIF-2 repeats downregu-
lated SV40 promoter activity, while one copy of MIF-2 se-
quences had no e¡ect. Similar results were reported in other
studies of the SV40 enhancer where a single binding site which
works in conjunction with the adjacent cis acting sites did not
exhibit transcriptional activity, but could be active in dimer-
ized or multimerized form [26,27]. These studies suggested
that the interaction between cooperating cis acting elements
and their binding factors could be compensated by the dupli-
cation of a functional site which could then interact with itself
to regulate transcription. The MIF-1 site is located adjacent to
three additional protein binding elements in intron I of the
c-myc gene and it has been proposed that these sites work
together to regulate promoter activity [5]. Thus, isolation of
the genes that encode MIBP1, p105 and p115 would allow to
study the cooperation of these binding factors and to examine
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their role in the regulation of c-myc, MHC class II and viral
gene expression.
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